Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma
Aim Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women. HCC varies widely in incidence through the world, with rising incidence in Egypt. This study aimed to estimate the serum levels of matrix metalloproteinase-9 (MMP-9) and its substrate galectin-3 in or...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2015-10, Vol.21 (5), p.323-330 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 330 |
|---|---|
| container_issue | 5 |
| container_start_page | 323 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 21 |
| creator | Eisa, Nada H Ebrahim, Mohamed A Ragab, Maha Eissa, Laila A El-gayar, Amal M |
| description | Aim
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women. HCC varies widely in incidence through the world, with rising incidence in Egypt. This study aimed to estimate the serum levels of matrix metalloproteinase-9 (MMP-9) and its substrate galectin-3 in order to evaluate their diagnostic accuracy and their relation to HCC-related clinical features.
Methods
For this purpose, serum levels of these biochemical markers were assessed in 50 HCC patients, 30 cirrhotic patients in addition to 10 healthy subjects as a control group using enzyme linked immune-sorbent assay (ELISA).
Results
In the present study, circulating level of galectin-3, MMP-9 increased significantly in HCC as compared to the control group (P = 0.044 and 0.04, respectively). However, no significant difference was observed between cirrhotic and HCC patients (P = 0.231 and 0.193, respectively). Our study found that HCC patients with metastatic spread had a significant elevation of both serum galectin-3 and MMP-9 levels (P = 0.028 and |
| doi_str_mv | 10.1177/1078155214532698 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1707555518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155214532698</sage_id><sourcerecordid>1707555518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-292c24e5a7b5387da5f54571b66bd0e3d6621caa6e3a88f1adec756ee7dbf0dd3</originalsourceid><addsrcrecordid>eNp1kM1LxDAQxYMouq7ePUnBi5dqkjYf9SaLX7CgBwVvdZpMtdKma9KK_vdmWRVZcC4zML9583iEHDB6wphSp4wqzYTgLBcZl4XeIBOWK5XSgj9uxjmu0-V-h-yG8Eop1YrrbbLDcyULwfSEPF1Bi2ZoXJol4GzSweCbj6TDAdq2X_h-wMZBwLQ4S-7Qh8USfsekcRF18IwduiHp6-QFFzD0Btt2bMEnBrxpXN_BHtmqoQ24_92n5OHy4n52nc5vr25m5_PUZFIMKS-44TkKUJXItLIgapELxSopK0sxs1JyZgAkZqB1zcCiUUIiKlvV1NpsSo5XutHz24hhKLsmLO2Aw34MJVNUiVhMR_RoDX3tR--iu0ix-EfxvIgUXVHG9yF4rMuFbzrwnyWj5TL9cj39eHL4LTxWHdrfg5-4I5CugBCT-_P1P8EvFh6NAw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1716217249</pqid></control><display><type>article</type><title>Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Eisa, Nada H ; Ebrahim, Mohamed A ; Ragab, Maha ; Eissa, Laila A ; El-gayar, Amal M</creator><creatorcontrib>Eisa, Nada H ; Ebrahim, Mohamed A ; Ragab, Maha ; Eissa, Laila A ; El-gayar, Amal M</creatorcontrib><description>Aim
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women. HCC varies widely in incidence through the world, with rising incidence in Egypt. This study aimed to estimate the serum levels of matrix metalloproteinase-9 (MMP-9) and its substrate galectin-3 in order to evaluate their diagnostic accuracy and their relation to HCC-related clinical features.
Methods
For this purpose, serum levels of these biochemical markers were assessed in 50 HCC patients, 30 cirrhotic patients in addition to 10 healthy subjects as a control group using enzyme linked immune-sorbent assay (ELISA).
Results
In the present study, circulating level of galectin-3, MMP-9 increased significantly in HCC as compared to the control group (P = 0.044 and 0.04, respectively). However, no significant difference was observed between cirrhotic and HCC patients (P = 0.231 and 0.193, respectively). Our study found that HCC patients with metastatic spread had a significant elevation of both serum galectin-3 and MMP-9 levels (P = 0.028 and <0.0001, respectively). In addition, galectin-3 level significantly increased in HCC patients with poor prognosis suffering from portal vein invasion (P = 0.014). Moreover, MMP-9 increased significantly with increasing stage of Barcelona-Clinic Liver Cancer Group diagnostic and treatment strategy (P = 0.01).
Conclusion
MMP-9 and galectin-3 could be used as a guide for prognosis of HCC since they may play a role in HCC progression and metastasis. However, they are not useful markers for HCC diagnosis.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155214532698</identifier><identifier>PMID: 24769518</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - pathology ; Case-Control Studies ; Egypt ; Enzyme-Linked Immunosorbent Assay ; Female ; Galectin 3 - blood ; Humans ; Liver cancer ; Liver Cirrhosis - blood ; Liver Cirrhosis - pathology ; Liver Neoplasms - blood ; Liver Neoplasms - diagnosis ; Liver Neoplasms - pathology ; Male ; Matrix Metalloproteinase 9 - blood ; Medical prognosis ; Middle Aged ; Neoplasm Metastasis ; Prognosis</subject><ispartof>Journal of oncology pharmacy practice, 2015-10, Vol.21 (5), p.323-330</ispartof><rights>The Author(s) 2014</rights><rights>The Author(s) 2014.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-292c24e5a7b5387da5f54571b66bd0e3d6621caa6e3a88f1adec756ee7dbf0dd3</citedby><cites>FETCH-LOGICAL-c365t-292c24e5a7b5387da5f54571b66bd0e3d6621caa6e3a88f1adec756ee7dbf0dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1078155214532698$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1078155214532698$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21799,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24769518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eisa, Nada H</creatorcontrib><creatorcontrib>Ebrahim, Mohamed A</creatorcontrib><creatorcontrib>Ragab, Maha</creatorcontrib><creatorcontrib>Eissa, Laila A</creatorcontrib><creatorcontrib>El-gayar, Amal M</creatorcontrib><title>Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Aim
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women. HCC varies widely in incidence through the world, with rising incidence in Egypt. This study aimed to estimate the serum levels of matrix metalloproteinase-9 (MMP-9) and its substrate galectin-3 in order to evaluate their diagnostic accuracy and their relation to HCC-related clinical features.
Methods
For this purpose, serum levels of these biochemical markers were assessed in 50 HCC patients, 30 cirrhotic patients in addition to 10 healthy subjects as a control group using enzyme linked immune-sorbent assay (ELISA).
Results
In the present study, circulating level of galectin-3, MMP-9 increased significantly in HCC as compared to the control group (P = 0.044 and 0.04, respectively). However, no significant difference was observed between cirrhotic and HCC patients (P = 0.231 and 0.193, respectively). Our study found that HCC patients with metastatic spread had a significant elevation of both serum galectin-3 and MMP-9 levels (P = 0.028 and <0.0001, respectively). In addition, galectin-3 level significantly increased in HCC patients with poor prognosis suffering from portal vein invasion (P = 0.014). Moreover, MMP-9 increased significantly with increasing stage of Barcelona-Clinic Liver Cancer Group diagnostic and treatment strategy (P = 0.01).
Conclusion
MMP-9 and galectin-3 could be used as a guide for prognosis of HCC since they may play a role in HCC progression and metastasis. However, they are not useful markers for HCC diagnosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Case-Control Studies</subject><subject>Egypt</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Galectin 3 - blood</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Matrix Metalloproteinase 9 - blood</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Prognosis</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kM1LxDAQxYMouq7ePUnBi5dqkjYf9SaLX7CgBwVvdZpMtdKma9KK_vdmWRVZcC4zML9583iEHDB6wphSp4wqzYTgLBcZl4XeIBOWK5XSgj9uxjmu0-V-h-yG8Eop1YrrbbLDcyULwfSEPF1Bi2ZoXJol4GzSweCbj6TDAdq2X_h-wMZBwLQ4S-7Qh8USfsekcRF18IwduiHp6-QFFzD0Btt2bMEnBrxpXN_BHtmqoQ24_92n5OHy4n52nc5vr25m5_PUZFIMKS-44TkKUJXItLIgapELxSopK0sxs1JyZgAkZqB1zcCiUUIiKlvV1NpsSo5XutHz24hhKLsmLO2Aw34MJVNUiVhMR_RoDX3tR--iu0ix-EfxvIgUXVHG9yF4rMuFbzrwnyWj5TL9cj39eHL4LTxWHdrfg5-4I5CugBCT-_P1P8EvFh6NAw</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Eisa, Nada H</creator><creator>Ebrahim, Mohamed A</creator><creator>Ragab, Maha</creator><creator>Eissa, Laila A</creator><creator>El-gayar, Amal M</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma</title><author>Eisa, Nada H ; Ebrahim, Mohamed A ; Ragab, Maha ; Eissa, Laila A ; El-gayar, Amal M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-292c24e5a7b5387da5f54571b66bd0e3d6621caa6e3a88f1adec756ee7dbf0dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Case-Control Studies</topic><topic>Egypt</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Galectin 3 - blood</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Matrix Metalloproteinase 9 - blood</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eisa, Nada H</creatorcontrib><creatorcontrib>Ebrahim, Mohamed A</creatorcontrib><creatorcontrib>Ragab, Maha</creatorcontrib><creatorcontrib>Eissa, Laila A</creatorcontrib><creatorcontrib>El-gayar, Amal M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eisa, Nada H</au><au>Ebrahim, Mohamed A</au><au>Ragab, Maha</au><au>Eissa, Laila A</au><au>El-gayar, Amal M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>21</volume><issue>5</issue><spage>323</spage><epage>330</epage><pages>323-330</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Aim
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women. HCC varies widely in incidence through the world, with rising incidence in Egypt. This study aimed to estimate the serum levels of matrix metalloproteinase-9 (MMP-9) and its substrate galectin-3 in order to evaluate their diagnostic accuracy and their relation to HCC-related clinical features.
Methods
For this purpose, serum levels of these biochemical markers were assessed in 50 HCC patients, 30 cirrhotic patients in addition to 10 healthy subjects as a control group using enzyme linked immune-sorbent assay (ELISA).
Results
In the present study, circulating level of galectin-3, MMP-9 increased significantly in HCC as compared to the control group (P = 0.044 and 0.04, respectively). However, no significant difference was observed between cirrhotic and HCC patients (P = 0.231 and 0.193, respectively). Our study found that HCC patients with metastatic spread had a significant elevation of both serum galectin-3 and MMP-9 levels (P = 0.028 and <0.0001, respectively). In addition, galectin-3 level significantly increased in HCC patients with poor prognosis suffering from portal vein invasion (P = 0.014). Moreover, MMP-9 increased significantly with increasing stage of Barcelona-Clinic Liver Cancer Group diagnostic and treatment strategy (P = 0.01).
Conclusion
MMP-9 and galectin-3 could be used as a guide for prognosis of HCC since they may play a role in HCC progression and metastasis. However, they are not useful markers for HCC diagnosis.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>24769518</pmid><doi>10.1177/1078155214532698</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2015-10, Vol.21 (5), p.323-330 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1707555518 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Aged Aged, 80 and over Biomarkers Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - pathology Case-Control Studies Egypt Enzyme-Linked Immunosorbent Assay Female Galectin 3 - blood Humans Liver cancer Liver Cirrhosis - blood Liver Cirrhosis - pathology Liver Neoplasms - blood Liver Neoplasms - diagnosis Liver Neoplasms - pathology Male Matrix Metalloproteinase 9 - blood Medical prognosis Middle Aged Neoplasm Metastasis Prognosis |
| title | Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T12%3A05%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Galectin-3%20and%20matrix%20metalloproteinase-9:%20Perspective%20in%20management%20of%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Eisa,%20Nada%20H&rft.date=2015-10-01&rft.volume=21&rft.issue=5&rft.spage=323&rft.epage=330&rft.pages=323-330&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155214532698&rft_dat=%3Cproquest_cross%3E1707555518%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1716217249&rft_id=info:pmid/24769518&rft_sage_id=10.1177_1078155214532698&rfr_iscdi=true |